China announces new crackdown on fentanyl

Image
IANS Beijing
Last Updated : Apr 01 2019 | 10:55 AM IST

The Chinese government on Monday announced that it will add fentanyl-related substances to their list of controlled drugs from May 1, in a move aimed at curtailing the manufacturing and distribution of one of the world's most powerful opioids.

The announcement was made jointly by the Ministry of Public Security, National Health Commission and the National Medical Products Administration at a press conference here, CNN reported.

Liu Yuejin, deputy head of China's National Narcotics Control Commission, called the move a "major innovative measure" in the country's contribution to the global war on drugs.

The top anti-narcotics official said the new regulation would prevent drug labs from evading the law by simply tweaking chemical structures of their products.

Liu stressed that China would enforce its laws "even more comprehensively" after the latest announcement and "bring violators to justice without mercy".

An extremely powerful synthetic drug, fentanyl is 50 to 100 times more potent than morphine and 30 to 50 times more potent than heroin.

According to the US Centre for Disease Control and Prevention, fentanyl was used in one in four overdose deaths in the US in 2018, killing just over 18,000 people in one year and overtaking heroin and oxycodone as the country's most deadly drug.

In March 2017, China banned the manufacture and sale of four types of fentanyl and later expanded the list to 25 types, but US President Donald Trump's administration had been pushing for a wider ban to slow the flow of the deadly drug into America.

Last August, Trump accused China of being behind the US' opioid crisis, claiming fentanyl was "pouring into the US postal system". In October 2018, Trump signed into law sweeping legislation to curb the epidemic, pouring billions of dollars of funding into treatment and prevention.

On Monday, Liu denied Washington's accusation that China was the primary source for fentanyl substances in the US, pointing a finger at US domestic issues ranging from over-prescription of painkillers to the powerful pharmaceutical lobby.

--IANS

ksk

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 01 2019 | 10:46 AM IST

Next Story